[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
March 2009

Intravenous Immunoglobulin Therapy for Dystrophic Calcinosis Cutis: Unreliable in Our Hands

Arch Dermatol. 2009;145(3):334. doi:10.1001/archdermatol.2008.620

We read with interest the recent report, “Response of Dystrophic Calcification to Intravenous Immunoglobulin,” by Schanz et al1 detailing the response to intravenous immunoglobulin (IVIg) of 1 patient with CREST syndrome–associated dystrophic calcification (CREST syndrome includes calcinosis cutis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia). Because the more traditional medical therapies, including warfarin, diltiazem hydrochloride, probenecid, colchicine, and bisphosphonates, are seldom reliable, newer safe and effective therapies are sought.2 Unfortunately, while the success reported by Schanz et al is encouraging, we have experienced less success with IVIg therapy for dermatomyositis-associated dystrophic calcification.

First Page Preview View Large
First page PDF preview
First page PDF preview